ShanX Medtech key facts
- Developer of a diagnostic platform designed to accelerate antibiotic susceptibility testing and improve infection management.
- It has raised $17.6M; the latest was Seed Round ($17.6M) in Jan 2026.
- Notable investors include European Commission, Brabantse Ontwikkelings Maatschappij, Invest-NL (Investment Company), Government of the Netherlands, Borski Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch ShanX Medtech: the Monday email on marks, rounds and moves
ShanX Medtech funding rounds
No funding rounds for ShanX Medtech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ShanX Medtech investors
9 investors are on record for ShanX Medtech, including European Commission, Brabantse Ontwikkelings Maatschappij, Invest-NL (Investment Company) and Government of the Netherlands.
About ShanX Medtech
Developer of a diagnostic platform designed to accelerate antibiotic susceptibility testing and improve infection management. The company's platform develops rapid Antibiotic Susceptibility Testing (AST) systems that integrate real-time analysis, portability and broad-spectrum pathogen profiling, enabling healthcare providers to identify effective treatments more fast and reduce patient risk, hospital stays and antimicrobial resistance.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2019
- Employees
- 11
- Website
- shanxmedtech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ShanX Medtech doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.